ALK-positive Non-small Cell Lung Cancer
Showing 1 - 4 of 4
ALK-positive NSCLC Trial in Dallas (Ceritinib, Stereotactic ablative body radiation)
Terminated
- ALK-positive Non-small Cell Lung Cancer
- Ceritinib
- Stereotactic ablative body radiation
-
Dallas, TexasUT Southwestern Medical Center
Jan 31, 2023
ALK-positive NSCLC Trial in Shanghai (Alkotinib Capsules)
Recruiting
- ALK-positive Non-small Cell Lung Cancer
- Alkotinib Capsules
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Nov 28, 2022
Stage IV NSCLC, Targeted Therapy, Nonsmall Cell Lung Cancer Trial in Boston (POISE)
Not yet recruiting
- Stage IV Non-small Cell Lung Cancer
- +7 more
- POISE
-
Boston, MassachusettsMassachusetts General Hospital
Apr 13, 2022
ALK-positive NSCLC Trial in Worldwide (Ceritinib)
Completed
- ALK-positive Non-small Cell Lung Cancer
-
Los Angeles, California
- +56 more
Apr 8, 2020